New combo therapy may help women with early breast cancer avoid mastectomy
NCT ID NCT06843681
First seen Jan 04, 2026 · Last updated Jun 11, 2026 · Updated 29 times
Summary
This study tests whether giving two drugs (trastuzumab and a taxane) before surgery can shrink HER2-positive breast carcinoma in situ tumors enough to allow breast-conserving surgery instead of mastectomy. About 54 women aged 18-70 with tumors at least 2 cm will receive 4-6 cycles of treatment. The main goal is to see how many can have breast-conserving surgery after therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CARCINOMA IN SITU are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, China
Conditions
Explore the condition pages connected to this study.